PRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Praxis Precision Medicines, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$260.17+18.41 (+7.61%)
Close on Oct 19, 2026
- Market cap
- $7.58B
- P/E (TTM)
- –
- Dividend yield
- –
Praxis Precision Medicines, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -45.8%
Financial strength
- Current ratio
- 15.73
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 967.8%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 5.65
- Dividend yield
- –